The purpose of this study was to evaluate pre-transplant T-cell status in autologous hematopoietic progenitor-cell transplantation (HPCT) recipients. Between 1999 and 2002 we prospectively enrolled 85 autologous HPCT recipients with solid tumors (N ¼ 50) or hematological
recovery; autologous transplantation
Autologous hematopoietic progenitor-cell transplantation (HPCT) has been extensively evaluated in patients with high-risk hematopoietic and solid tumors. Tumor relapse remains the major cause of treatment failure. Possible causes of recurrence include insufficient tumor ablation by the conditioning regimen, tumor contamination of the autologous graft, and failure of the immune system to mount an effective antitumor response after transplantation.
The role of immune effector cells in tumor biology is an active area of research. Evidence has accumulated that demonstrates an antitumor effect involving T cells in the allogeneic transplant setting, particularly for hematologic malignancies. For example, donor lymphocyte infusions produce a graft-versus-tumor effect capable of inducing sustained remissions in chronic myelogenous leukemia (CML).
1,2 Additionally, T-cell depletion of the allogeneic graft leads to increased risk for relapse from CML. [3] [4] [5] However, there is little evidence of an antitumor immune effect in the autologous HPCT setting.
Autologous HPCT recipients are immunocompromised for a variety of reasons. First, these patients are often T-cell deficient before transplant due to prior therapies. 6 Second, the intensity of the conditioning regimen itself causes immunosuppression lasting several months. 7 Third, they remain compromised for an extended period of time after transplant due to the involution of the thymus. 8 Fourth, the malignancy may deregulate the immune system. 9 To evaluate the prognostic significance of pre-transplant T-cell levels, we undertook a prospective study of pretransplant memory and naı¨ve T-cell levels.
Patients and methods

Patients, control individuals, and protocols
Between February 1999 and July 2002, 85 autologous HPCT recipients were prospectively enrolled in this pretransplant immune analysis study, which was approved by the University of Colorado Cancer Center Protocol Review Committee and the Institutional Review Board. All patients gave written informed consent before participating in this study. Patient diagnoses were breast cancer (N ¼ 49), non-Hodgkin's lymphoma (N ¼ 20), myeloma (N ¼ 11), Hodgkin's disease (N ¼ 3), germ-cell tumor (N ¼ 1), and amyloidosis (N ¼ 1) (Table 1) . Patients received a variety of high-dose chemotherapy (HDC) regimens, including cyclophosphamide/cisplatin/BCNU (CCB) (N ¼ 23), and single-agent melphalan (N ¼ 12). 12 In all, 13 patients with HER2/neu positive advanced BC were enrolled in a pilot study of concurrent administration of the anti-HER2/neu monoclonal antibody trastuzumab with CCB. 13 Then, 14 patients with refractory tumors were enrolled in a phase I study of docetaxel, melphalan, and carboplatin 14 T-cell levels from 25 healthy volunteers were analyzed as controls.
Flow cytometry
Blood was drawn at the pre-mobilization appointment by veni-puncture, and 40-60 ml collected in green top vacutainers (Becton Dickinson, Franklin Lake, NJ, USA). Complete blood counts (CBC) were performed on all blood samples using an ADVIA120 hematology system (Bayer Corporation, Norwood, MA, USA). T-cell levels were determined with monoclonal antibodies to CD3, CD4, CD8, and CD45 (Coulter, Miami, FL, USA). Naı¨ve T cells were identified by the presence of the CD45RA þ / CD45ROÀ or CD45RA þ /CD62L þ immunophenotypes. [15] [16] [17] Additionally, memory T cells were identified by the presence of CD45RO þ , CD45RAÀ/CD62LÀ, CD45RAÀ/CD62L þ , or CD45RA þ /CD62LÀ immunophenotypes. 14, 15 The monoclonal antibodies used in the analyses of naı¨ve and memory cells were obtained from the following companies CD3 (Coulter, Miami, FL, USA), CD4, CD8, CD45RA, CD45RO, CD62L, IgG2b, IgG2a, and IgG1 (Becton Dickinson, San Jose, CA, USA). Samples were analyzed by four-color flow cytometry with a Coulter XL flow cytometer.
Statistical analyses
Progression-free survival (PFS) was defined as the time from study entry to a documented progression or death without progression. Overall survival (OS) was defined as the time from study entry to death from any cause. Both survival times were analyzed using the Kaplan-Meier method. 18 Univariate analysis of the different immunologic counts with PFS and OS were made using the two-sided log-rank test. 19 Patients were segregated based on the median count of each lymphocyte subset.
Multivariate analysis for PFS and OS used the stepwise proportional hazards regression method. 20 These models included the immunologic variables with significance at the level of Po0.05 in the univariate analyses, along with other variables considered predictors of clinical relevance. Such variables were tumor type, tumor stage, tumor sensitivity at transplant, and HER2/neu status for breast cancer patients. The significance of the models was evaluated with the likelihood ratio test. Individual coefficients were tested using the Wald test. The proportionality assumption for all variables was assessed with KaplanMeier curves.
Associations between the pre-transplant counts for the different lymphocyte subsets were assessed using the Spearman correlation test. All P-values were two tailed. Statistical calculations were performed using the Statistica 5.1 1997 edition (StatSoft Inc, Tulsa, OK, USA).
Results
Patient outcome
Patient follow-up ranged from 4-60 months with a median of 30 months. In the solid tumor subgroup, 22 of the 23 patients with high-risk primary breast cancer and eight of the 26 patients with metastatic breast cancer, as well as the patient with germ-cell tumor, remained free of progression. Among patients with hematological malignancies, 14/20 patients with non-Hodgkin's lymphoma, 5/11 with myeloma, 2/3 with Hodgkin's disease, and the patient with amyloidosis remained progression free. 
Comparison of pre-transplant counts of autologous HPCT recipients with controls
Median pre-transplant white blood cell (WBC) counts in our patients were not significantly different from controls: 3890/ml (range, 540-27 300/ml) vs 6580/ml (4350-9830) (P ¼ 0.13). In contrast, patients had lower pre-transplant CD3 T-cell counts than controls: 670/ml (5-2880) vs 1440/ml (625-3113) (Po0.00001) (Figure 1) . Similarly, they presented lower pre-transplant CD4 T-cell counts: 360/ml (3-1900) vs 1020/ml (412-2880) (Po0.00001), but not CD8 T-cell counts: 260/ml (3-2700) vs 399/ml (155-1900) (P ¼ 0.17) (Figure 1 ). Patients had significantly lower naive CD4CD45RA þ CD45ROÀ T-cell counts: 111/ml (1-741) vs 362 (171-1040) (Po0.0001), but not naive CDCD45RA þ CD62L þ T-cell counts: 33/ml (4-162) vs 64 (6-377) (P ¼ 0.27). Patients had significantly lower memory CD4CD45RO þ T-cell counts 320/ml (56-1040) vs 580/ml (184-1120) (Po0.05), memory CD4CD45RAÀCD62LÀ T-cell counts: 391/ml (76-1160) vs 276/ml (32-887) (Po0.03), but not memory CD4CD45RA þ CD62LÀ T-cell counts: 28/ml (8-413) vs 47/ml (3-969) (P ¼ 0.26), or memory CD4CD45RAÀCD62L þ T-cell counts: 179/ml (40-1170) vs 293/ml (32-737) (P ¼ 0.16).
Univariate prognostic analyses
Higher pre-transplant CD4 T-cell levels correlated with PFS (P ¼ 0.002) ( Figure 2 ) and OS (P ¼ 0.05) in the overall group. Additionally, pre-transplant CD4 T-cell counts correlated with PFS both in the breast cancer group (P ¼ 0.04) (Figure 3) , and in patients with hematological malignancies (P ¼ 0.02).
Higher pre-transplant levels of the memory subset CD4 þ CD45RAÀCD62LÀ T-cells correlated with PFS in the overall group (P ¼ 0.01) (Figure 4) , without reaching statistical significance with respect to OS (P ¼ 0.1).
No significant associations with PFS or OS were observed for the pre-transplant levels of the following cell populations: CD3, CD8, CD4 memory subsets CD45RA-CD62L þ and CD45RA þ CD62LÀ, CD4 naı¨ve subsets CD45RA þ CD62L þ and CD45RA þ CD45ROÀ, and all memory or naı¨ve CD8 T-cell subsets in any patient group (data not shown).
Multivariate prognostic analyses
Separate multivariate models included pre-transplant CD4 T cells and CD4 þ CD45RAÀCD62L-memory T cells along with clinical variables, such as tumor diagnosis, tumor sensitivity, and stage. These analyses showed independent value for pre-transplant CD4 T-cell levels on T-cell counts in the overall patient group.
PFS (P ¼ 0.005) and OS (P ¼ 0.03) (Table 2a) , and for CD4 þ CD45RAÀCD62LÀ memory T cells on PFS (P ¼ 0.001) (Table 2b) . A model for PFS in breast cancer patients combined pretransplant CD4 T-cell counts, tumor stage, sensitivity, and HER2/neu status (Table 3 ). In this model, CD4 T-cell counts (P ¼ 0.04), and stage (P ¼ 0.01) were independent predictors. Of note, all HER2 þ patients received trastuzumab as part of the transplant high-dose regimen, which might potentially explain the lack of effect of HER2 status in this analysis.
Discussion
Evaluation of CD4 T-cell levels in our study demonstrated that half of the autologous HPCT recipients, prior to their mobilization, contain CD4 T-cell levels below the lowest observed value for controls. Our observations are consistent with multiple prior immune recovery reports, 21, 22 and confirm the immunodeficiency of this patient population. In addition, there are differences in the extent of pretransplant deficiency between subsets of naı¨ve and memory CD4 T cells. Further, we observe an important prognostic effect of CD4 T-cell levels, specifically memory CD4 þ CD45RAÀCD62LÀ T-cell levels, independently of other known predictors. Despite the different patient populations, our joint analysis of both hematological malignancies and breast cancer show similar prognostic effect of pretransplant CD4 T-cell levels.
The associations observed in this study require confirmation, further research into possible contributing factors and mechanisms, and a similar analysis post transplant. A future confirmatory study with a larger, more homogenous patient population is warranted. Continued research into the possible contribution of prior chemotherapies and disease on pre-transplant CD4 T-cell levels and outcome are necessary. In addition to the T-cell levels, future association of the results of T-cell functional assays with outcome is useful. In our study, patients often are followed at outside institutions, and due to gradual decrease in sample availability, we did not attempt to correlate post transplant levels of immune cells with outcome. Therefore, future prognostic studies of post transplant T-cell reconstitution are crucial.
Our prospectively collected data suggest a relationship between the pre-transplant status of the immune system and tumor control after HDC. While a potential role of the immune system in this scenario generates considerable interest, there is actually minimal data regarding its prognostic impact. Recent retrospective observations of a correlation between early absolute lymphocyte recovery and outcome in patients with solid tumors and hematological malignancies, suggest the possibility of an immune component to relapse. [23] [24] [25] [26] [27] Furthermore, Porrata et al 28 show a correlation of the actual lymphocyte content of the autologous graft with early post transplant lymphocyte counts with outcome patients with NHL, and in myeloma patients. 29 Additionally, CD4 T-cell counts associate with survival in patients with multiple myeloma treated on an Eastern Cooperative Oncology Group phase III trial comparing three different nontransplant approaches. 30 These observations, combined with the results of the present study, suggest the existence of a tumor-primed memory CD4 þ CD45RAÀCD62LÀ T-cell population in patients undergoing an autologous transplant, which may play a role in control of minimal residual disease after transplant. Consistent with this concept, CD4 þ CD45RAÀCD62LÀ memory T cells are known for their ability to mediate cell-mediated immunity. 31 The original development and progression of tumors may occur prior to the development of a cell-mediated immune response capable of controlling the malignant disease. The debulking capacity of HDC may offer those patients with a more robust T-cell status a chance to control their tumors after massive cytoreduction. Further research into the prognostic impact of CD4 and CD4 þ CD45RAÀCD62LÀ memory T cells, as well as the mechanisms of immune recovery, are crucial to the development of effective immunotherapeutic approaches in autologous transplantation. Over the past few years, several immune strategies have been evaluated in patients with hematological malignancies receiving an autologous HPCT, such as pre and post transplant use of interleukin-2 to increase mobilization of immune effector cells into the graft and their immunoreactivity, [32] [33] [34] [35] post transplant reinfusion of autologous lymphokine-activated killer cells, 36, 37 or of antigen-pulsed dendritic cells. 38 Likewise, use of cytokines before 39, 40 or after transplant, [41] [42] [43] [44] or cellular therapy following autologous transplantation, 45, 46 have been also tested in patients with breast cancer. Our results suggest the possibility that an insight into the individual pre-transplant immune status may allow the tailoring of post transplant immune strategies according to different risk categories.
In conclusion, our data suggest that the immune system, and more specifically peripheral CD4 T cells and the memory CD4 þ CD45RAÀCD62LÀ T-cell subset, may play an important role in tumor control after HDC. Our observations support the investigation of pre and post transplant immune trials in the autologous transplant setting directed at promoting the antitumor effect of peripheral T cells. Characterization of the role of the immune system in tumor control in autologous transplantation may have implications on cancer treatment in general.
